Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergy Drug Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

NCT02147808
View directory record Official record
Conditions
Drug Interactions
Interventions
Telotristat etiprate, Midazolam
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

NCT02521363
View directory record Official record
Conditions
Breast Cancer
Interventions
KIBUR MICRODEVICE, anthracycline and taxane based chemotherapy
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

NCT00000886
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 C4-V3 Polyvalent Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Increasing Adherence to Asthma Medication in Urban Teens

NCT00269282
View directory record Official record
Conditions
Asthma
Interventions
Self-Management Training, Motivational Interviewing (MI)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 15 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting No phase listed Observational

Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)

NCT07343024
View directory record Official record
Conditions
Advanced Cancer
Interventions
Not listed
Lead sponsor
Cancer Commons
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Inhaler Trainer Efficacy Study

NCT06461403
View directory record Official record
Conditions
Asthma, Copd, Acute Exacerbation of COPD
Interventions
Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
Device · Other
Lead sponsor
Koronis Biomedical Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
C1-esterase inhibitor [recombinant] (C1-INH-R)
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

NCT02319616
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Clobetasol 0.05% ointment, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
7 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

NCT00445874
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (no generic name)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Irvine, California • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Sep 25, 2026, 4:13 AM EDT
Not yet recruiting Not applicable Interventional

Asthma Ctrl SMART Trial

NCT07512622
View directory record Official record
Conditions
Asthma in Children, Asthma Chronic
Interventions
Asthma Ctrl+, Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Assess the Suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) Device

NCT05592769
View directory record Official record
Conditions
Respiratory Disease
Interventions
HealthBeacon Injection Care Management System (ICMS)
Device
Lead sponsor
HealthBeacon Plc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Best African American Response to Asthma Drugs

NCT01967173
View directory record Official record
Conditions
Asthma
Interventions
Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, Flovent Diskus® 500 mcg, Advair Diskus® 100/50 mcg, Advair Diskus® 250/50 mcg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Phase 4 Interventional

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

NCT02163005
View directory record Official record
Conditions
Contrast Media Allergy
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
56 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

NCT02099656
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 25, 2026, 4:13 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Effect of Chinese Herbal Medicine on Food Allergy

NCT00602160
View directory record Official record
Conditions
Food Allergy
Interventions
FAHF-2 (TM)
Drug
Lead sponsor
Li, Xiu-Min, M.D.
Individual
Eligibility
12 Years to 45 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Drug Sensitivity and Mutation Profiling

NCT04956198
View directory record Official record
Conditions
Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Wilms Tumor, Sarcoma, Spindle Cell, Sarcoma Rhabdoid, Childhood Sarcoma of Soft Tissue
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
Up to 21 Years
Enrollment
14 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 1 Interventional

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

NCT06952010
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Interventions
XB628, Zanzalintinib
Biological · Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional

Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

NCT04088981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dietary intervention
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional

Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents

NCT02426814
View directory record Official record
Conditions
Asthma
Interventions
Inhaler sensor, Mobile application for asthma adherence
Device · Behavioral
Lead sponsor
CoheroHealth
Industry
Eligibility
11 Years to 19 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

NCT00557180
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Beclomethasone dipropionate HFA, Tiotropium bromide, Salmeterol xinafoate
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 25, 2026, 4:13 AM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Photocil (Topical) for the Treatment of Atopic Dermatitis

NCT01992172
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Photocil for Atopic Dermatitis, Placebo - Sunscreen (SPF 2)
Drug · Other
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Ragweed Observational Study

NCT01398137
View directory record Official record
Conditions
Ragweed Allergy
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 25, 2026, 4:13 AM EDT